文献速递生殖医学妇科

体外受精与胚胎植入前遗传学检测预防BRCA1/2突变传递的成本效果分析

Cost effectiveness of in vitro fertilisation and preimplantation genetic testing to prevent transmission of BRCA1/2 mutations.
PubMed 文献 · Hum Reprod · 2020-01-01

该研究采用状态转换模型,比较经IVF/PGT-M出生的健康子代与自然受孕活产(半数为BRCA突变携带者)的医疗影响。

要点

  • 在5万加元/QALY阈值下,IVF/PGT-M对BRCA1/2突变携带者均具成本效果。
  • 概率敏感性分析显示成本效果概率分别为98.4%和97.3%。

核心结论

  • 在每QALY 5万加元的支付意愿阈值下,IVF/PGT-M对BRCA1和BRCA2突变携带者均具成本效果。

研究设计与样本

  • 采用状态转换模型,比较IVF/PGT-M出生的健康子代队列与自然受孕活产队列(半数为BRCA突变携带者)。
  • 模型基于已发表来源的转移概率,采用终身时间跨度,视角为加拿大省级卫生部。

主要发现

  • 概率敏感性分析显示,在5万加元/QALY阈值下,IVF/PGT-M对BRCA1和BRCA2突变携带者具有成本效果的概率分别为98.4%和97.3%。

关键数值与推荐

  • 支付意愿阈值为每QALY 5万加元。
  • 成本效果概率:BRCA1为98.4%,BRCA2为97.3%。

临床怎么用

  • 在单一支付者医疗体系中,支付方覆盖BRCA突变携带者夫妇的IVF/PGT-M费用可能具有成本效果。

局限性

  • 模型未纳入IVF/PGT-M对女性生活质量的短期负面影响。
  • 模型未考虑与植入后遗传学检测相关的伦理问题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Is it cost-effective to use in vitro fertilisation and preimplantation genetic testing of monogenic defects (IVT/PGT-M) to prevent transmission of BRCA1/2 mutations to second-generation new births in comparison with naturally conceived births? SUMMARY ANSWER: In this cost-effectiveness analysis, we found that IVF/PGT-M is cost-effective for BRCA1 and BRCA2 mutation carriers if using a willingness to pay of $50 000 per quality-adjusted life-year (QALY). WHAT IS KNOWN ALREADY: Carriers of a BRCA1 or BRCA2 mutation have a significantly increased risk of several types of cancer throughout their lifetime. The cost of risk reduction, screening and treatment of cancer in this population is high. In addition, there is a 50% chance of passing on this genetic mutation to each child. One option to avoid transmission of an inherited deleterious gene to one's offspring involves in vitro fertilisation with preimplantation genetic testing. STUDY DESIGN, SIZE, DURATION: We implemented a state transition model comparing the healthcare impact of a cohort of healthy children born after IVF/PGT-M, who have a population risk of developing cancer, to a cohort of naturally conceived live-births, half of whom are carriers of the BRCA mutation. Transition probabilities are based on published sources, a lifetime horizon and a perspective of a provincial Ministry of Health in Canada. PARTICIPANTS/MATERIALS, SETTING, METHODS: The target population is the second-generation new births who have at least one parent with a known BRCA1 or BRCA2 mutation. MAIN RESULTS AND THE ROLE OF CHANCE: At a willingness-to-pay threshold of $50 000 per QALY, IVF/PGT-M is a cost-effective intervention for carriers of either BRCA mutation. For BRCA1, the incremental cost-effectiveness ratio (ICER) for IVF/PGT-M is $14 242/QALY. For BRCA2, the ICER of intervention is $12 893/QALY. Probabilistic sensitivity analysis results show that IVF/PGT-M has a 98.4 and 97.3% chance of being cost-effective for BRCA1 and BRCA2 mutation carriers, respectively, at the $50 000/QALY threshold. LIMITATIONS, REASONS FOR CAUTION: Our model did not include the short-term negative effect of IVF/PGT-M on the woman's quality of life; in addition, our model did not consider any ethical issues related to post-implantation genetic testing. WIDER IMPLICATIONS OF THE FINDINGS: In countries in which the healthcare of a large segment of the population is covered by a single payer system such as the government, it would be cost-effective for that payer to cover the cost of IVF/PGT-M for couples in which one member has a BRCA mutation, in order to avoid the future costs and disutility of managing offspring with an inherited BRCA mutation. STUDY FUNDING/COMPETING INTEREST(S): Dr Wong's research program was supported by the Canadian Institutes of Health Research (CIHR), the Natural Sciences and Engineering Research Council (NSERC), the Canadian Liver Foundation and an Ontario Ministry of Research, Innovation and Science Early Researcher Award. All authors declared no conflict of interests.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Lipton JH, Zargar M, Warner E, et al. Cost effectiveness of in vitro fertilisation and preimplantation genetic testing to prevent transmission of BRCA1/2 mutations. Hum Reprod. 2020. PMID: 32099994. doi:10.1093/humrep/dez203

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。